drugset / Trial / NCT04869501
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
Summary
This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Atezolizumab | Monoclonal antibody | — | — |
| Background | Uliledlimab | Monoclonal antibody | — | — |